As the ketogenic diet’s popularity rises, certain considerations need to be taken when recommending it for patients with Type 1 diabetes.
New Analysis of Old Trial Results Offers Insights Into Personalized Care for Type 2 Diabetes
New research indicates a previously unrecognized genetic subtype of patients with type 2 diabetes at high risk for cardiovascular disease who may benefit from intensive glycemia treatment.
Prediction Model Estimates Anticipated Weight Loss from Four Common Anti-Obesity Medications
In a new study, Cleveland Clinic researchers the examine weight loss achieved in 12 weeks by patients with prescriptions for anti-obesity medication. In this article, Bartolome Burguera, MD, PhD, and Kevin Pantalone, DO, share their results as well as the weight loss prediction calculator they developed to aid in shared decision-making.
Testosterone Replacement Therapy Does Not Increase or Decrease Cardiovascular Risk, Study Finds
Treating men with secondary hypogonadism may not be necessary, but may reduce symptoms and related comorbidities. Endocrinologist Kevin Pantalone, DO, discusses the findings of his latest research, which found that testosterone replacement therapy did not affect cardiovascular risk, and calls for larger studies to evaluate the safety of this therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Patient-Specific Therapy Selection Critical in Order to Avoid Intensification Inertia
Defining intensification inertia as a unique phenomenon and exploring other barriers to the successful treatment of type 2 diabetes.
Cleveland Clinic Employees Part of Study Looking at Effectiveness of Anti-Obesity Meds and Shared Medical Appointments
Endocrinology & Metabolism Institute is partnering with Novo Nordisk to study the effectiveness of the health system’s employee health plan-sponsored integrated weight management program, with and without the use of medications.
Standing with New Recommendations to Report Lower Hypoglycemia Levels
Endocrine specialist explains why the recording of low blood glucose levels in clinical trials should be standardized.
Study Looks at Managing New T2D Patients
Cleveland Clinic research evaluates intensification of diabetes therapy and hemoglobin A1C (A1C) goal attainment among patients with newly-diagnosed type 2 diabetes who fail metformin monotherapy.
DPP-4 Inhibitors and Congestive Heart Failure
A Cleveland Clinic retrospective study finds DPP-4 therapy neutral, in terms of myocardial infarction and death; and its benefits in controlling glycemia while avoiding hypoglycemia and weight gain should be considered.